As we head into the weekend, I’ve been trying to come up with new superlatives to describe how Lilly and Novo Nordisk are doing. To say their results were spectacular is an understatement but also not at all surprising. These two longtime rivals are just killing it, and this is just the beginning. Think of where sales will be when they fix their manufacturing issues and reimbursement improves. Not to be harsh but as good as sales are now, they have just scratched the surface of the obesity market.
Even better both have strong pipelines which look very promising . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.